{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T02:16:21Z","timestamp":1789870581555,"version":"4.0.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,3,22]],"date-time":"2017-03-22T00:00:00Z","timestamp":1490140800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.cllc.2017.03.011","type":"journal-article","created":{"date-parts":[[2017,3,23]],"date-time":"2017-03-23T23:07:36Z","timestamp":1490310456000},"page":"e385-e394","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Feasibility Study of Personalized Peptide Vaccination for Advanced Small Cell Lung Cancer"],"prefix":"10.1016","volume":"18","author":[{"given":"Shinjiro","family":"Sakamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teppei","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Terazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Yoshiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichi","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinzo","family":"Takamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Matsueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Shichijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyogo","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuoki","family":"Kohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Sasada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2017.03.011_bib1","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S1470-2045(13)70511-4","article-title":"Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study","volume":"15","author":"Kubota","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2017.03.011_bib2","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1158\/1078-0432.CCR-14-2958","article-title":"Small cell lung cancer: will recent progress lead to improved outcomes?","volume":"21","author":"Pietanza","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2017.03.011_bib3","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ejca.2014.12.006","article-title":"PD-L1 expression in small cell neuroendocrine carcinomas","volume":"51","author":"Schultheis","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cllc.2017.03.011_bib4","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3892\/etm.2011.424","article-title":"Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis","volume":"3","author":"Yoshitomi","year":"2012","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.cllc.2017.03.011_bib5","first-page":"1492","article-title":"Personalized peptide vaccination in patients with refractory non-small cell lung cancer","volume":"40","author":"Yoshiyama","year":"2012","journal-title":"Int J Oncol"},{"key":"10.1016\/j.cllc.2017.03.011_bib6","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.3892\/or.2013.2556","article-title":"A\u00a0phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients","volume":"30","author":"Yutani","year":"2013","journal-title":"Oncol Rep"},{"key":"10.1016\/j.cllc.2017.03.011_bib7","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00262-012-1379-1","article-title":"Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine","volume":"62","author":"Noguchi","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.cllc.2017.03.011_bib8","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.2174\/0929867321666140205132936","article-title":"Personalized peptide vaccine for treatment of advanced cancer","volume":"21","author":"Sasada","year":"2014","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.cllc.2017.03.011_bib9","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1158\/1078-0432.CCR-1117-3","article-title":"Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses","volume":"10","author":"Mine","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2017.03.011_bib10","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.4161\/cbt.10.12.13448","article-title":"Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination","volume":"10","author":"Noguchi","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.cllc.2017.03.011_bib11","first-page":"57","article-title":"Characteristics of severe adverse events after peptide vaccination for advanced cancer patients: analysis of 500 cases","volume":"25","author":"Yoshida","year":"2011","journal-title":"Oncol Rep"},{"key":"10.1016\/j.cllc.2017.03.011_bib12","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/00365510410007008","article-title":"New multiplexed flow cytometric assay to measure anti-peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization","volume":"64","author":"Komatsu","year":"2004","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.cllc.2017.03.011_bib13","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.dci.2013.04.004","article-title":"Humoral immune responses to CTL epitope peptides from tumor-associated antigens are widely detectable in humans: a new biomarker for overall survival of patients with malignant diseases","volume":"41","author":"Matsueda","year":"2013","journal-title":"Dev Comp Immunol"},{"key":"10.1016\/j.cllc.2017.03.011_bib14","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/cas.12226","article-title":"Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients","volume":"104","author":"Takahashi","year":"2013","journal-title":"Cancer Sci"},{"key":"10.1016\/j.cllc.2017.03.011_bib15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3892\/ijo.2014.2699","article-title":"Feasibility study of personalized peptide vaccination for advanced non-small cell lung cancer patients who failed two or more treatment regimens","volume":"46","author":"Yamada","year":"2015","journal-title":"Int J Oncol"},{"key":"10.1016\/j.cllc.2017.03.011_bib16","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1200\/JCO.2010.29.7499","article-title":"Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen\u2014A24 with recurrent or progressive glioblastoma multiforme","volume":"29","author":"Terasaki","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2017.03.011_bib17","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1349-7006.2012.02202.x","article-title":"Immunological evaluation of personalized peptide vaccination in refractory small cell lung cancer","volume":"103","author":"Terazaki","year":"2012","journal-title":"Cancer Sci"},{"key":"10.1016\/j.cllc.2017.03.011_bib18","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1200\/JCO.2013.54.5392","article-title":"Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer","volume":"32","author":"von Pawel","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2017.03.011_bib19","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1158\/2326-6066.CIR-14-0035","article-title":"Phase II study of personalized peptide vaccination for previously treated advanced colorectal cancer","volume":"2","author":"Kibe","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.cllc.2017.03.011_bib20","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/1521-4141(200102)31:2<323::AID-IMMU323>3.0.CO;2-0","article-title":"Recognition of the Lck tyrosine kinase as a tumor antigen by cytotoxic T lymphocytes of cancer patients with distant metastases","volume":"31","author":"Harashima","year":"2001","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.cllc.2017.03.011_bib21","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/ijc.1461","article-title":"Identification of Lck-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with distant metastases","volume":"94","author":"Imai","year":"2001","journal-title":"Int J Cancer"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730417300888?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730417300888?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:07:32Z","timestamp":1761505652000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730417300888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S1525730417300888"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2017.03.011","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Feasibility Study of Personalized Peptide Vaccination for Advanced Small Cell Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2017.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}